Lilly (Eli)

Eli Lilly is one of the world's most valuable pharmaceutical companies, with leading franchises in diabetes and obesity, oncology, immunology and neuroscience. Its incretin therapies for diabetes and weight loss have driven a surge in demand, reshaping the company into a dominant force in metabolic medicine alongside a deep pipeline in Alzheimer's and other areas. Lilly has paid dividends for more than a century and raised them consistently for decades, but the yield has fallen to a very low level as the share price has climbed steeply. The payout is comfortably covered by rising earnings, with growth prioritized over yield. A high score reflects a dependable, long-growing dividend attached to an exceptionally strong and expanding franchise.